The chemotherapy drug cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants through an immune system cell that evades the toxic effects of cyclophosphamide.
The occurrence of venous thromboembolism (VTE) is greater than has been identified in clinical trials, according to a large-scale analysis that assessed the real-world risk.
Results from a new study could benefit some children with high-risk AML. A therapeutic regimen that combined the GO with conventional three-drug chemotherapy was associated with improved survival in children with AML who underwent bone marrow transplantation.
Giving trastuzumab and anthracyclines concurrently is not necessary to achieve a high rate of complete pathologic remission in HER2-positive breast cancer. The results of a recent phase III clinical trial show that administering the treatments sequentially is equally effective.
Adult patients with Burkitt lymphoma had excellent long-term survival rates—upwards of 90%—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding.
Selectively targeting only cancer cells could help to avoid healthy cells and side effects from treatments.
A phase II study is the first to show that adding two targeted therapy drugs to the standard chemotherapy regimen is safe and effective as first-line treatment of advanced non-small cell lung cancer.
Sequentially combining gemtuzumab ozogamicin and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia.
A new combination of a poly ADP-ribose polymerase (PARP) inhibitor drug and conventional platinum-based chemotherapy may extend the lives of women with ovarian cancer, according to a new study.
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival, compared with observation alone.
Oncologists are adding new agents to their arsenal against mantle cell lymphoma.
Advances in treatments, better risk assessment, and effective supportive care are leading to better outcomes for patients with lung cancer.
Working with cells in test tubes and in mice, researchers discovered that a chemical commonly used as a dog food preservative prevents chemotherapy-associated peripheral neuropathy.
Losartan, an angiotensin inhibitor used to treat hypertension, may improve the delivery of chemotherapy drugs and oxygen to solid tumors.
An analysis of quality-of-life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy with chemotherapy showed a significantly lower QOL at 3 months after treatment compared with patients who received a standard dose of radiation with chemotherapy.
The FDA approved Perjeta (pertuzumab) for the neoadjuvant treatment of breast cancer, first generic version of Xeloda (capecitabine) has gained FDA approval, and other FDA actions.
Adult survivors of childhood cancers who underwent certain chemotherapy treatments or kidney surgery had worse kidney function, which did not recover over time.
Chemotherapy can improve median survival by more than 6 months in elderly persons with small cell lung cancer (SCLC), a retrospective cohort study has indicated.
What is the impact of nicotine use on the efficacy of chemotherapy? What information is important to discuss with patients who continue to smoke while on chemotherapy?
Why are ketones present in urinalysis results when patients are receiving ifosfamide or cyclophosphamide?
Survivors of Hodgkin lymphoma who received subdiaphragmatic radiotherapy had dose-dependent increased risk for stomach cancer, researchers discovered.
A newly discovered weakness in cancer cells may make them more susceptible to chemotherapy and other treatments.
Survival up for patients with early breast cancer, especially for hormone-receptor positive tumors, after treatment with response-guided neoadjuvant chemotherapy.
A new study provides the first direct evidence that the deadly epithelial-to-mesenchymal transition occurs in humans during metasis, at least in patients with ovarian cancer.
Giving men with testicular cancer a single dose of chemotherapy alongside radiotherapy could improve the effectiveness of treatment and reduce the risk for long-term side effects, according to a new study.
A whole new class of drugs has been developed that targets the structure of the cancer cell for the first time.
Patients with diffuse large B-cell lymphoma, which often relapses and kills within 2 years, experienced a remission of their cancer and stayed disease-free as long as 28 months after taking a commercially available drug that made chemotherapy more effective.
About 15% of patients with glioblastoma could receive personalized treatment with drugs currently used in other cancers, based on new research that has identified 18 genes responsible for driving glioblastoma multiforme.
New research suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.
A clinical evaluation demonstrates the effectiveness of a mucoadhesive polymer rinse on oral mucositis, a common side effect of radiotherapy.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|